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Targeted PEGylated liposomes could increase the amount of drugs or radionuclides delivered to tumor cells. They show favorable
stability and pharmacokinetics, but steric hindrance of the PEG chains can block the binding of the targeting moiety. Here,
speciﬁc interactions between an antihapten antibody (clone 734, speciﬁc for the DTPA-indium complex) and DTPA-indium-
tagged liposomes were characterized by surface plasmon resonance (SPR). Non-PEGylated liposomes fused on CM5 chips whereas
PEGylatedliposomesdidnot.Bycontrast,bothPEGylatedandnon-PEGylatedliposomesattachedtoL1chipswithoutfusion.SPR
binding kinetics showed that, in the absence of PEG, the antibody binds the hapten at the surface of lipid bilayers with the aﬃnity
of the soluble hapten. The incorporation of PEGylated lipids hinders antibody binding to extents depending on PEGylated lipid
fraction and PEG molecular weight. SPR on immobilized liposomes thus appears as a useful technique to optimize formulations
of liposomes for targeted therapy.
1.Introduction
The development of liposomes capable of targeting cells has
been an objective since the 80s [1, 2]. The most prevalent
method is to conjugate antibodies or antibody-based con-
structs (e.g., fragments or single chain Fv) directly on
their surface (i.e., immunoliposomes). However, the ability
of immunotargeted liposomes to deliver high doses of
drugs or radioactivity to tumor cells in vivo remains to be
demonstrated, partly because it is diﬃcult to include all
necessary features, that is, long circulation times, stable
drug encapsulation or radiolabeling with high activities, and
eﬃcient antibody targeting in the liposomes preparation [3].
Other antibody constructs, such as bispeciﬁc antibodies,
provide an alternative way to speciﬁcally target liposomes
to cancer cells [4]. The bispeciﬁc antibody is used here as
a pretargeting agent. It recognizes both a tumor-speciﬁc
antigenandasmallmolecule(thehapten)usedasatagtothe
liposome membrane. The pretargeting system presents the
advantageofusingastablebispeciﬁcantibodyandliposomes
that can be loaded extemporaneously with drugs or radionu-
clides, whereas stability and loading of immunoliposomes
may be a problem. We have developed a liposomes radiola-
beling method which is based on an active-loading approach
for obtaining high speciﬁc activity-labeled liposomes [5].
Thus, the use of liposome as delivery systems represents2 Journal of Drug Delivery
an attractive alternative to vehicle important quantities of
radionuclides.
Recent formulations of liposomes prevent their opson-
ization by serum proteins and thus enhance residence
time in the bloodstream. This is obtained by the addition
of PEG functionalized lipids in their composition [6–8].
Diﬀerent PEGylated liposomes formulations bearing the
DTPA-indium hapten at their surface have been tested. Such
PEGylated liposomes, also referred to as stealth liposomes,
containing doxorubicin and a few other drugs have been
approved for marketing. Liposomes containing 1.5%, 5%,
or 8% PE-PEG were analysed for blood clearance over
24h after injection in mice. Rapid elimination of con-
ventional liposomes and 1.5% PEGylated liposomes was
observed. Incorporation of 5% PEG in liposome consid-
erably increased the retention time in bloodstream. The
experiment showed identical half life and clearance (13,06h
and 0.16mL/h or 13,89h and 0.20mL/h, resp.) for 5 and 8%
DSPE-PEG, indicating that 5% DSPE-PEG is suﬃcient to
obtain a maximum blood residence time [9]. Nevertheless,
preliminary in vivo results have shown an improvement
by only a factor of 1.7 between passive tumor targeting
(absence of bispeciﬁc antibody) and active targeting of the
liposomes by prior injection of a bispeciﬁc antibody binding
carcinomembryonic antigen (CEA) on one arm and the
DTPA-indium hapten on the other, in a model of CEA-
positive tumor xenografts in the mouse. Passive targeting
of the liposomes through the well-known enhancement
permeability and retention eﬀect [5] is very signiﬁcant, and,
therefore, to be interesting, active targeting of the liposomes
to the tumor sites must be more eﬃcient than what we
observedwiththesehapten-taggedPEGylatedliposomes.Itis
long known that PEGylation can hinder speciﬁc recognition
between immunoliposomes and target cells [10]. Steric
hindrance may also be the reason for the poor enhancement
of tumor uptake caused by the bispeciﬁc antibody. Since
this phenomenon has never been studied in a quantitative
manner, we decided to use surface plasmon resonance
(SPR) to characterize the speciﬁc interactions between the
antihapten antibody and hapten-tagged liposome as a model
of speciﬁc immunologic interaction at the liposome surface
in the presence of varying amounts of PEGylated lipids
and various PEG chain lengths. SPR is a technique that
is frequently applied for measuring binding rate constants
between two interacting entities, generally proteins. Its most
obvious advantages over other techniques are: direct and
rapid determination of association and dissociation rates
of binding process and no need of labeling liposomes.
Several studies have demonstrated that the technique is
sensitive enough to monitor interactions between solutes
and lipid bilayers like liposomes. Artiﬁcial bilayer lipid
membranes (BLMs) have been extensively used to mimic
biological cell membranes for studying membrane processes
such as signal transduction, ligand-receptor interactions,
and ion transport through cell membranes [11–13]. Recent
advancesinthepreparationofstablemembrane-likesurfaces
and the commercialization of sensor chips has enabled
widespread use of SPR in analyzing these protein-membrane
interactions in an environment that closely resembles our
in vivo situation [14–16]. In this study, tethered bilayer
membrane on CM5 chips and nonfused liposomes immo-
bilized on L1 chips have been used to monitor by SPR the
binding of antibodies to conventional and PEGylated DTPA-
indium-tagged liposomes. We compared several liposomes
formulations composed of distearoylphosphatidylcholine
(DSPC), cholesterol (Chol), DSPE-DTPA that varied in their
PEG content and molecular weight (2000, 1000, or 750).
Binding kinetics of a speciﬁc anti-indium-DTPA antibody
(clone 734) were monitored using the BIAcore system and
the kinetic parameters were calculated by curve ﬁtting.
2.MaterialsandMethods
2.1. Materials and Equipment. The puriﬁed MAb 734IgG,
with binding speciﬁc for the DTPA-indium complex, was
kindly provided by IBC Pharmaceuticals (Morris Plains, NJ).
All chemicals were dissolved in sterile water (versol or
versylene, FRESENIUS, France). Phosphate buﬀered saline
(PBS 9.55g·L−1, PBS DULBECCO) was supplied by BIO-
CHROM AG, (Berlin, Germany). 0.4M N-ethyl-N-(3-dim-
ethylaminopropyl)-carbodiimide hydrochloride and 0.1M
N-hydroxysuccinimide (NHS) were obtained from GE
Healthcare. Dimyristoyl-L-α-phosphatidylethanolamine (D-
MPE), Triton-X100 (t-octylphenoxypolyethoxyethanol) and
stable indium-115 chloride (115In) were purchased, res-
pectively, from Sigma-Aldrich and Sigma Ultra. Radioactive
indium-111 chloride (111In) was purchased from Mallinc-
krodt (Petten, The Netherlands).
Other phospholipids used to prepare liposomes were:
1,2-Distearoyl-sn-glycerol-3-phophoethanolamine-N-[Me-
thoxy(Polyethylene glycol)-2000] M.W:2805.54 (DSPE-
PEG2000),1,2-Distearoyl-sn-glycerol–3-phophoethanolam-
ine-N-[Methoxy(Polyethylene glycol)-1000] M.W:1631.37
(DSPE-PEG1000), 1,2-Distearoyl-sn-glycerol-3-phophoeth-
anolamine-N-[Methoxy(Polyethylene glycol)-750] M.W:
1528 (DSPE-PEG750), and 1,2-Distearoyl-sn-glycerol-3-ph-
ophoethanolamine-N-[Methoxy(Polyethylene glycol)-550]
M.W:1351.78 (DSPE-PEG550) were purchased from Avanti
Polar Lipids (Alabaster, AL, USA). (DSPE-DTPA) was syn-
thesized by Ecole Nationale Sup´ erieure de Chimie de Rennes
(France). Vesicle extruder and ﬁlter supports were purchased
from Avanti Polar Lipids, Inc. Polycarbonate membranes for
vesicle extrusion (100nm or 200nm pore size, Nucleopore)
were from Whatman. All phospholipids were dissolved in
9:1 chloroform/methanol mixture (HPLC grade, Carlo Erba
and Fisher Scientiﬁc, resp.).
2.2. MAb 734 Equilibrium Binding Assays in Coated Tubes.
Avidin-coated tubes saturated with bovine serum albu-
min (BSA) were used for equilibrium aﬃnity constant
determinations of the anti-DTPA-indium antibody (MAb
734) in competition experiments between DTPA-111In as
a tracer and stable DTPA-metal complexes. Brieﬂy, 1mL
of a 50ng/mL solution of biotinylated Mab 734Fab frag-
ment was incubated overnight at 4◦C in the avidin coated
tubes. Just before use, the tubes were washed with NaCl
0.9%-Tween 20 0.05%. DTPA (0.1nmol) was labeled withJournal of Drug Delivery 3
commercial indium-111 chloride (5 × 107 cpm) and used
as a tracer (15000cpm in a total incubation volume of
0.3mL). Incubation with varying concentrations of stable
DTPA-metal or EDTA-metal competitors was performed
overnight at 4◦C in PBS supplemented with BSA. Tubes
were then counted after two rapid washes with 2mL of
NaCl-Tween.
2.3. DMPE Solubilization for CM5 Coating. Dimyristoyl-
L-α-phosphatidylethanolamine (DMPE) was thoroughly
mixed with PBS containing 1% Triton-X100 (t-octylphenox-
ypoly-ethoxyethanol) to a ﬁnal concentration of 1mg·mL−1,
followed by at least three freeze-thaw cycles, ultrasonication,
and incubation at 55◦C.
2.4. Liposomes Preparation and Characterization. For vesicles
preparation, the desired phospholipids (DSPC) in organic
solvent CHCl3/MeOH (9:1) were transferred to a 10mL
round bottom ﬂask and the solvent was evaporated to
dryness. PBS was then added to the lipid ﬁlm for a ﬁnal lipid
concentration of 20μmol·mL−1.
Large unilamellar vesicles (LUVs) composed of DSPC,
DSPC/DSPE-DTPA (98:2 molar ratio) or DSPC/Chol/
DSPE-DTPA (68:30.5:1.5 molar ratio) were prepared
according to the lipid ﬁlm hydration method [17]f o l -
lowed by extrusion. Typically, for the nonfused liposomes,
13.5μmol of phospholipids, 6.6μmol of cholesterol, and
0.3μmol of phospholipids coupled to the chelating agent
(DTPA) were dissolved in chloroform/methanol (9:1v/v)
in a 10mL round bottom ﬂask. DSPE-PEG2000 (0.5mol%,
1.5mol%, 2.5mol%, 3.5mol%, or 5mol%) were included in
the preparation according to the necessity of experimenta-
tion.
A thin dry ﬁlm of lipids was obtained by evaporation
of the solvents in a rotary evaporator. Hydration of the dry
lipids was accomplished by addition of 1mL of aqueous
phase and maintained above the gel crystal transition
temperature of the lipids during all the hydration procedure.
To this eﬀect, the ﬂask containing the liposomes suspension
wasmixedduring2honarotaryevaporationsystemwithout
vacuum, at room temperature for conventional liposomes
(DSPC), and 74◦C for DSPC/Chol/DSPE-DTPA PEGylated
liposomes.Typically,theﬁnalconcentrationoftheliposomes
suspension was 20μmol of lipids per mL of aqueous phase.
Toobtainsmallandhomogeneousvesicles,theliposomes
suspension was sonicated times to time in a bath-type son-
icator then 20 times extruded through Nucleopore 100nm
polycarbonate ﬁlters using a manual thermostat heated
extrusion device at room temperature for conventional
liposomes and at 74◦C for PEGylated liposomes [18]. The
size and polydispersity of the vesicles were measured by
dynamic laser light-scattering system using a Malvern High
Performance Particle Sizer (HPPS-ET, Instrument SA, UK).
Measurements were performed in triplicate after dilution
of the suspension in water. The mean size were 101 ±
4nm (polydispersity index <0.1) for conventional liposomes
and 107 ± 3nm (polydispersity index <0.1) for PEGylated
liposomes with all concentrations of PEG2000.
2.5. 115 In Loading Procedure. DTPA functionalized lipo-
somes were prepared in citrate (0.10M)/acetate (0.15M)
buﬀer, pH = 5.3. Nonradioactive indium (115In) chloride
in HCl 0.02N was added with a ratio of 10 indium molar
equivalentspermoleoflipids,andthemixturewasincubated
for 2 hours at 37◦C. Then, 115In-loaded liposomes were
separated from free indium by gel ﬁltration chromatography
using a PD-10 column eluted in PBS.
2.6. Formation of Lipid Planar Bilayers on CM5 Chips. Freely
a c c e s s i b l et e r m i n a lc a r b o x y lg r o u p so ft h ed e x t r a nl a y e rw e r e
activated with N-ethyl-N’-(3-dimethylaminopropyl)-carbo-
diimide hydrochloride) (EDC) and N-hydroxysuccinimide
(NHS). The primary amine of dimyristoyl-L-α-phosph-
atidylethanolamine (DMPE) was then reacted with the
activated succinimide esters overnight at 55◦C. This reaction
yields the proximal monolayer of the lipid membrane that is
covalently attached to the dextran layer on the gold surface.
Then, the DMPE-coated surface was thoroughly rinsed with
distilled water and the chip was docked again in the BIAcore
instrument. All ﬂow cells were washed three times with
30μL100mMNaOH(ﬂowrate30μL/min).DMPEcoupling
provides the highly hydrophobic surface necessary for the
subsequent functionalization of the tethered membrane by
spontaneous vesicle spreading. Lipid vesicles or liposomes
werethenspreadontheDMPElayertoconstitutethe bilayer.
Brieﬂy, liposomes (1mg/mL in PBS) were injected over the
h y d r o p h o b i cs u r f a c ef o rf o u rt ot e nm i n u t e sa taﬂ o wr a t eo f
10μL/min.
2.7. Binding of Intact Liposomes to L1 Chips. The BIAcore
3000 instrument equipped with the L1 chip was used
for Surface Plasmon Resonance measurement of antibody
binding to nonfused liposomes. The surface of the chip was
conditioned with three consecutive injections for 1min at
30μL/min of isopropanol/50mM NaOH (2/3, v/v).
Liposomes (1mg/mL in PBS) were deposited on three
ﬂow cells for 10min at ﬂow rate of 5μL/min. The liposomes
surface was washed with NaOH 100mM for 1min at
30μL/min. Bound liposomes could be removed from the
L1 surface at the end of the experiments by two 1-minute
injections of 50mM NaOH:isopropanol (2/3, v/v) followed
by two injections of Chaps 2% (w/v). Surface binding of L1
biosensor chip can be regenerated as often as needed.
2.8. Atomic Force Microscopy (AFM). A multitask AFM
CP was used for AFM imaging in the tapping mode and
topographic measurements. Typically for the analysis, we
observed the presence of a tethered lipid bilayer modiﬁed
area and a nonmodiﬁed surface.
2.9. Kinetic Measurements. For all measurements, the ﬂow
rate was ﬁxed at 60μL/min. Serial two-fold dilutions of
MAb 734 were prepared (750nM to 0.78nM) and injected
over on either the tethered planar bilayer on CM5 sensor
chip or nonfused liposomes immobilized on the L1 sensor
chip. Dilutions of MAb 734 were injected from low to high
concentration in a single-cycle kinetic (SCK) mode with4 Journal of Drug Delivery
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Figure 1: MAb 734 binding with DTPA-indium hapten. Inhibition
of DTPA-111Indium binding to biotinylated MAb734 coated to
avidin tubes as a function of DTPA-indium or EDTA-indium
concentration. The equilibrium aﬃnity constants were calculated
from the data using standard Scatchard analysis.
association phases monitored for 3min at 60μL/min and
allowing 4min dissociation phases.
2.10. Data Analysis. The resulting sensorgrams were ﬁtted
using a mathematical program based on single cycle kinetic
model implemented in BIAeval 4.1 software (BIAcore).
3. Results
3.1.MAb734—DTPA-IndiumBindingCharacterization. The
MAb 734 was originally screened for its binding to solu-
ble DTPA-indium complex [19]. Competition experiments
(Figure 1) using tubes coated with MAb 734 allowed the
equilibrium dissociation constant to be determined as
0.3nM at 4◦C.
3.2. CM5 Bilayer
3.2.1. Formation of Lipid Planar Bilayers on CM5 Sensor
Chip. DMPE was used for the setup of tethered artiﬁcial
membranes by chemical coupling of the primary amino
groups with succinimide esters of the dextran carboxylate
groups. Then, the three formulations of liposomes, PEGy-
lated,andconventionalwerespreadontheDMPEmonolayer
after rinsing with PBS. Figure 2 shows that liposomes give a
stable signal of 1100RU. This value is in agreement with the
expected RU of the second monolayer coating of the CM5
sensor chip functionalized with DMPE.
Figure 3 emphasizes that (a) DSPC-containing lipid
vesicles spread and formed a 900RU tethered planar bilayer-
and (b) DSPC/DSPE-DTPA-Indium-containing lipid vesi-
cles also spread but formed a 1100RU tethered planar bilayer
whereas (c) DSPC/DSPE-DTPA-Indium/DSPE-PEG2000-
containing lipid vesicles were not able to spread on the
DMPE-monolayer.
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Figure 2: Tethered planar bilayer formation on DMPE function-
alized CM5 chip. A BIAcore CM5 chip was coated with DMPE as
described in materials and methods. The functionalized chip was
treated with DSPC/DSPE-DTPA containing vesicles at a 5μL/min
ﬂow rate. The sensorgram shows the spreading of liposomes to a
level of 1100RU and the formation of a stable planar bilayer.
Our formulation (DSPC/DSPE-DTPA-Indium-contain-
ing lipid vesicles) induced a gain of 200RU compared to
the standard formulation (DSPC-containing lipid vesicles)
(Figures 3(a) and 3(b)).
Although conventional liposomes (non-PEGylated) gave
satisfactory results, it was not possible to create a lipid planar
bilayer with the PEGylated liposomes (Figure 3(c)). This can
be explained by the fact that PEG-chains constitute a barrier
against spreading on the DMPE layer.
A CM5 sensor chip coated with the model bilayer ob-
tained by fusing conventional liposomes to the DMPE
layer was examined with an Atomic Force Microscope
(AFM). Images clearly showed the topographical structure
of lipid planar bilayers overlaying the dextran matrix and no
liposomes stuck to the dextran as single particles conﬁrming
previous ﬁndings on either the characterization of planar
supportedbilayers[20]orthebehavioradoptedbyliposomes
adsorbedonCM5andL1sensorchipswithmodiﬁeddextran
matrix [15, 21]. We could assume that liposomes fuse to
form a lipid planar bilayer on the top of the dextran matrix
which is the upper component of CM5 chips. Moreover, it
has already been demonstrated that liposomes adsorbed on
L1 chips surfaces may remain as intact single vesicles.
3.2.2. MAb 734 Binding to DTPA-Indium Coupled to Lipid
PlanarBilayer. TheaﬃnityofMAb734totheDTPA-indium
functionalized lipid planar bilayer was tested on a BIAcore
3000instrumentinasinglecyclekineticmodel.Theantibody
bound the DTPA-indium hapten coupled to the DSPE layer
without binding to the control DSPC layer. The binding was
followed in real-time by a sensorgram resulting from the
single-cycle kinetics assays on the functionalized bilayer after
subtraction of the control DSPC ﬂow cell. The interaction is
highlyspeciﬁcinthisrangeofconcentration.Theassociation
and dissociation rate constants were calculated using the
single cycle kinetics model also called “titration kinetics
model.” The kinetic constants for MAb 734 binding toJournal of Drug Delivery 5
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Figure 3: Formation of tethered planar bilayers on DMPE-functionalized CM5 chip with liposomes of diﬀerent lipid compositions. A
DMPE-coated chip was treated with liposomes prepared with 4 diﬀerent lipid compositions: (a) DSPC-containing lipid vesicles that
spread and formed a 900RU tethered planar bilayer, (b) DSPC/DSPE-DTPA-indium-containing lipid vesicles that spread and formed a
1100RU tethered planar bilayer, and (c) DSPC/DSPE-DTPA-indium/DSPE-PEG-containing lipid vesicles that were unable to spread on the
hydrophobic DMPE monolayer.
the DTPA-indium-functionalized bilayer calculated using
this procedure of global ﬁtting are listed in Table 1.T h e
ratio of the kinetic constants (koﬀ/kon)p r o v i d e daKD value,
1.6nM, similar to those determined in the equilibrium
binding experiments.
3.3. L1 Chip. A control surface was prepared by loading
vesicles without DTPA-Indium on the ﬁrst ﬂow cell of a
L1 sensor chip, resulting in the deposition of 15000RU. As
indicatedinFigure 4, conventional andPEGylated liposomes
were properly adsorbed on the sensor chip with approxi-
mately the same level of absorbance (15–16000RU). It was
not possible to rule out vesicle fusion on the surface of
the L1 chip by a direct observation with the AFM. We
assume that the liposomes are adsorbed intact. In addition,
previous published data “strongly” suggested that vesicles
remain intact once bound to the lipophilic anchors on
the surface of L1 chips [22, 23]. Therefore, these vesicles
still maintain their biophysical properties. This ﬁnding has
been conﬁrmed by the characterization of calcein-loaded
immobilized liposomes [24].
Then, MAb 734 binding kinetics to the surface of
L1 chip which has been coated with diﬀerent types of
liposomes (DSPC/Chol/DSPE-DTPA (68:30.5:1.5), DSPC/
Chol/DSPE-DTPA/DSPE-PEG2000 (63:30.5:1.5:5)) was
monitored as above.
The calculated aﬃnity constant (KD = 1.6 × 10
−9 M)
for conventional liposomes was exactly the same as the
value obtained with planar bilayer formed by conventional
liposomes on CM5 (Table 1). The surface of the ﬁrst ﬂow
cell coated with vesicles without DTPA-indium was used as
a nonspeciﬁc binding control. In addition, antibody binding
was observed only on liposomes surfaces functionalized with
DTPA loaded with indium (data not shown).
3.3.1. Inﬂuence of DSPE-PEG Molar Fraction. The binding
responses shown in Figure 5 illustrate that DTPA-indium-
functionalized liposomes prepared with DSPE-PEG2000 at
various concentrations (0.5%–1.5%–2.5%–.5%) bound the
antibody with an aﬃnity that strongly decreased with
the DSPE-PEG2000 fraction (MAb 734 antibody-binding6 Journal of Drug Delivery
Table 1: Analysis of MAb 734 binding on tethered DSPC/DSPE-DTPA-indium bilayer created on CM5 chip and of MAb 734 binding
to DTPA-indium-tagged liposomes adsorbed onto a L1 chip via kon (1/Ms), koﬀ (1/s), Rmax (RU), and KD (M) parameters. MAb 734
was prepared in two-fold serial concentration series (720nM to 2.185nM) and was injected at a ﬂow rate 60μL/min across the liposomes
adsorbed L1 chip surface for 3min. At the end of each injection, the dissociation phase was set to 4min. Liposomes binding assay was only
performed once with CM5 and duplicated with L1 chip. kon and koﬀ values were obtained by nonlinear regression of experimental data ﬁtted
with the SCK mathematical model. The score of χ2 (Chi2) is <5; it means that the model used adequately describes our data. kon, koﬀ,a n d
KD values are the average ± standard deviations.
Chip kon (1/Ms) koﬀ (1/s) Rmax KD (M)
CM5 5.57 105 8.99 10−4 80.7 1.60 10−9
L1 5.08 ±0.04 105 8.03 ±0.03 10−4 1970 1.58 ±0.01 10−9
Table 2: Analysis of MAb 734 binding with DSPC/Chol/DSPE-
DTPA-indium/DSPE-PEG2000 liposomes via kon (1/Ms), koﬀ (1/s),
and KD (M). The amount of DSPE-PEG contained in PEGylated
liposomes varied from 0% to 5%. Liposomes were immobilized on
L1 chip. The length of PEG chain was ﬁxed unchanged at 2000. The
DTPA amount was ﬁxed. The score of χ2 (Chi2) is <5; it means
that the model used adequately describes our data. All experiments
were duplicated. kon, koﬀ,a n dKD values are the average ± standard
deviations.
Formulations
(%DSPE-
PEG2000)
kon (1/Ms) koﬀ (1/s) KD (M)
0% 5.08 ±0.04 105 8.03 ±0.03 10
−4 1.59 ±0.01 10
−9
0.5% 3.31 ±0.38 105 8.03 ±0.07 10
−4 2.45 ±0.26 10
−9
1.5% 1.52 ±0.23 105 1.21 ±0.13 10
−3 8.04 ±0.39 10
−9
2.5% 6.01 ±0.07 104 2.06 ±0.05 10
−3 3.28 ±0.12 10
−8
3.5% 1.02 ±0.25 104 2.68 ±0.02 10
−3 2.78 ±0.63 10
−7
5% // /
responses were normalized for the level of liposomes cap-
tured on each surface, making it possible to compare the
binding results directly). This eﬀect was observed when the
DTPA-indium hapten was directly coupled to DSPE (DSPE-
DTPA). Using the same ﬁtting procedure (SCK model),
the kinetic constants for MAb734 binding were calculated
for the diﬀerent percentages of PEGylated lipid in the
liposomes preparations (Table 2). Thus, the higher aﬃnity
was observed for the non-PEGylated liposomes. When the
concentration of DSPE-PEG2000 was increased from 0 to
3.5%, kon reduced about 40 times while koﬀ increased about
3 times. The Rmax value seems to follow the same decrease
as the association rate. From these ﬁndings, we can assume
that the DTPA-indium haptens are masked by the PEGylated
chains of DSPE-PEG2000. More precisely, the diminution
of association rate constant and Rmax can be almost totally
explained by the steric eﬀects of the PEGylated chains that
reduce the diﬀusion factor. The faster dissociation rates may
be attributed to a decrease of rebinding during the dissoci-
ation phase that can also be explained by steric hindrance.
Botheﬀectscombinedinincreasingthedissociationconstant
from 1.6nM in the absence of DSPE-PEG to over 1μMw i t h
3.5% of DSPE-PEG2000.
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Figure 4: Deposition and absorption of liposomes on an L1 chip.
Liposomes were deposited on the L1 chip for 5min at 5μL/min
in PBS. The concentration of lipids was 1mg/mL. The ﬂow rate
was changed to 30μL/min after the deposition, and liposomes were
washed with three consecutive injections of NaOH in increasing
concentration(20,50,and100mM).AllvesicleswereinPBSduring
the injection. A control surface was prepared by loading PEGylated
liposomeswithoutDTPA-indiumontheﬁrstﬂowcellofaL1sensor
chip (DSPC/Chol/DSPE-PEG2000).
3.3.2. Inﬂuence of DSPE-PEG Chain Size. The binding
responses shown in Table 3 emphasize that DTPA-indium-
functionalized liposomes prepared with DSPE-PEG at vari-
ous sizes (DSPE-PEG750–DSPE-PEG1000) bound the anti-
body with a much higher aﬃnity for DSPE-PEG750 com-
pared to DSPE-PEG2000 at the same concentration (2.5%
of DSPE-PEG). The antibody was also able to bind the
liposomeswithahigherconcentrationofDSPE-PEG750(6%
and8%ofDSPE-PEG).LiposomesPEGylatedwithPEG1000
gave an aﬃnity which was intermediate but higher than the
one obtained with DSPE-PEG2000.
4. Discussion
The fundamental properties of unconjugated liposomes
(e.g., size, surface charge, PEGylation, and membrane
ﬂuidity) that largely determine their fate in vivo have
been identiﬁed [10, 25], and their eﬀect on liposomes
biodistributions and pharmacokinetics has been studied and
understood to a great extent. However, the presence of
surface conjugated-ligands (antibodies, protein fragments,
and haptens) in targeted liposomes introduces additional
complexities in their interactions with the biological milieu.Journal of Drug Delivery 7
Table 3: Data of KD (M) and Rmax (RU) resulted from MAb 734 binding with DSPC/Chol/DSPE-DTPA-indium/DSPE-PEG750 and
DSPC/Chol/DSPE-DTPA-indium/DSPE-PEG1000 liposomes in order to emphasize the inﬂuence of PEG chain size. Three diﬀerent
concentrations of DSPE-PEG (2.5%, 6%, and 8%) were studied for each size of PEG chain. The score of χ2 (Chi2) is <5; it means that
the model used adequately describes our data. Experiments were duplicated. KD value is the average ± standard deviations.
%DSPE-PEG 2.5% 6% 8%
PEG Size KD (M) Rmax (RU) KD (M) Rmax (RU) KD (M) Rmax (RU)
750 2.29 ±0.11 10−9 1081 8.57 ±0.08 10−9 902 2.51 ±0.15 10−8 845
1000 4.25 ±0.21 10−9 688 5.48 ± 0.22 10−8 529 1.15 ±0.44 10−7 424
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Figure 5: MAb 734 binding to DTPA-indium-tagged liposomes
adsorbed onto a L1 chip. Kinetic titration series of MAb 734
on DSPC/DSPE-DTPA-indium-containing liposomes with various
DSPE-PEG 2000 concentrations deposited on an L1 chip. The
liposomes were deposited on the L1 Chip at the same level of
Resonance Units, approximately 15 000RU. For each formulation,
MAb 734 was prepared in two-fold serial concentration series
(720nM to 2.185nM) and was injected at a 60μL/min ﬂow rate
across the liposomes adsorbed on the L1 chip surface for 3min. At
the end of each injection, the dissociation phase was set to 4min.
A better understanding of these interactions will result in
better targeted liposomes for maximum targeting speciﬁcity.
At this point, it is clear that addition of PEG to the liposomes
surface is needed to prevent opsonisation, fast uptake of
the liposomes in the liver, and rapid clearance. Introducing
immunospeciﬁc ligands in the liposome membrane can
target the liposomes and their content, but PEG chains
interfere with antibody recognition. This steric hindrance
is observed when an antibody is attached to the liposomes
surface [10] but also, as shown in this paper, when the
liposomeistaggedwithasmallmolecularweightligandtobe
recognizedbyanantibodyor,asdescribedbyCaoandSuresh
[4], by a bispeciﬁc antibody. This study also demonstrates
that biosensors and SPR may be used to quantify this
phenomenon of steric hindrance as a function of the fraction
of PEGylated lipids added to the liposomes and as a function
of the length of the PEG chains.
Using CM5 chips, tethered bilayers are obtained upon
addition of non-PEGylated liposomes. CM5 chip provides
us with the development of a tethered bilayer obtained by
the spreading of non-PEGylated liposomes that yielded us
to determine information on kinetics and thermodynamics.
This model oﬀered the advantages of controlling more
precisely the bilayer formation and above all the quantity
and the saturation degree of hapten used for the calculation
of binding rates. The antihapten antibody then binds to the
hapten coupled to phospholipids and incorporated into the
liposomes preparation. The binding kinetics between MAb
734 and the indium-DTPA hapten bound to these non-
PEGylated phospholipid bilayers showed speciﬁc binding
with an aﬃnity value of 1.6×10
−9 M, close to that measured
in a completely diﬀerent system of immobilized antibody
and soluble radiolabeled indium-DTPA hapten, which may
be considered as a mirror situation. This ﬁrst experiment
provides us with reference-binding rates and dissociation
constants obtained both by kinetics and equilibrium mea-
surements. Unfortunately, DPSE-PEG containing liposomes
appeared not to bind and fuse on the surface of these
CM5 chips. This may be easily explained by the hydrophilic
barrier created by PEG chains at the surface of the liposomes
preventing the interaction with the hydrophobic surface of
the chip. Thus, L1 chips were used and shown capable
of binding both conventional and PEGylated liposomes,
independentlyoftheDSPE-PEG2000molarratio,PEGchain
length, and the addition of hapten-bearing phospholipids.
Although AFM could not demonstrate directly that the
liposomes attached to the L1 chips remain intact, indirect
evidence has been published in the literature in favor of this
hypothesis [22–24]. L1 chips were coated with liposomes
prepared with diﬀerent lipid compositions to very similar
RU signals. It is diﬃcult to ascertain that this means that
the number of liposomes or the number of indium-DTPA
molecules attached to the chip is identical with PEGylated
and non-PEGylated liposomes. However, this means that the
orders of magnitude of these numbers are similar. Besides,
the kinetic analysis used to derive binding constants is not
d e p e n d e n to nt h i sn u m b e r .T h e s ed i ﬀerences in binding
aﬃnities must reﬂect steric hindrance from the PEG chains
and not a problem of liposomes capture. Thus binding
of preformed liposomes of various compositions to L1
chips provides a robust and versatile system for in vitro
binding studies of antibodies directed against liposome-
bound antigens, using SPR.
The incorporation of PEGylated lipids in the liposome
membrane hinders antibody binding in a PEGylated lipid
fraction-dependent manner. The concentration and the
chain length of PEGylated lipids are limiting factors for
antibody-liposome interaction. Results from these binding8 Journal of Drug Delivery
studies show that hapten-tagged vesicles prepared with
DSPE-PEG2000 at a ratio equal to or greater than 5%
are poorly recognized by the antihapten antibody. The
relativeaﬃnityoftheantibody forhapten-bearingliposomes
decreased from 1.6 × 10
−9 Mt o1 .1 × 10
−7 M when the
PEGylated lipid percentage increased from 0% to 5%. We
have looked into the variations of speed and diﬀusion
coeﬃcients in real-time. Rate constants measured by SPR
revealed decreased diﬀusion coeﬃcients of the antibody
with vesicles containing various concentrations of DSPE-
PEG2000 that translated in kon values decreasing with the
PEG concentration. Similarly, Rmax value showed a decrease
of the availability of haptens.
All these phenomena could be physically explained by
the relative pliability and ﬂexibility of PEG chain and its
unspeciﬁc interactions in equilibrium with the positive
charge molecules present at the surface of liposomes. PEG
chain with a relatively long size induces a steric hindrance, a
diﬀusing diﬃculty of the antibodies to the hapten site. The
masking of these haptens results in kon decreasing value and
a decrease of Rmax. Nevertheless, once the antibodies are
bound to their haptens the intensity of the interactions is not
modiﬁed and only the rebinding capacity is diminished, that
is traduced by a less increasing of koﬀ value.
Liposomes prepared with shorter PEG chains—DSPE-
PEG750 or DSPE-PEG1000—have more tightly bound the
anti-hapten antibody, thus showing less steric hindrance.
The shorter the chain, the easier the antibody MAb 734
diﬀuses, the higher the kon, and the higher the aﬃnity for the
antibody-hapten interaction. These three eﬀects may be the
result of two phenomena: PEG chain sweeping is inﬂuenced
by the chain length and the formation of a tight mesh of PEG
chains is inﬂuenced by the PEG concentration. Clearly, size
and concentration of PEG chains limit the mass transfer of
antibodies to their binding sites. Shorter PEG chains—even
at high concentrations—should improve in vivo targeting
because the aﬃnity decreased only to 2.5 × 10
−8 Ma n d
5.5 × 10
−8 M with, respectively, 8% of DSPE-PEG750 or 6%
of DSPE-PEG1000.
As the shorter PEG chains are more rigid, they are less
capable of sweeping and unspeciﬁcally interacting with the
liposomes. The less PEG chain interfere with the diﬀusion
of antibodies and the masking of haptens, the less kinetics
constant are modiﬁed and the more PEG concentration
could be increased without loss in aﬃnity.
The ﬁrst in vivo pretargeting experiments, with PEGy-
lated radiolabeled liposomes prepared with 5% of DSPE-
PEG2000 and bispeciﬁc antibodies, showed encouraging but
insuﬃcient results with a tumor uptake increased by a factor
of 1.7, compared to passive targeting of conventional lipo-
somes. The results of this study by SPR reveal and quantify
a large loss of hapten-antibody aﬃnity with such a formula-
tion. The pharmacokinetic parameters of the other formula-
tions have been evaluated (data not shown) showing reason-
ably long circulation times, particularly with liposomes con-
taining 6% or 8% of shorter PEG chains (750 or 1000). Since
these liposomes formulations show reduced steric hindrance
for the hapten—antibody interactions, they will be tested for
pretargeted delivery of radionuclides to tumors in vivo.
5. Conclusion
SPR biosensors, such as BIAcore, are most often used to
measurethebindingkineticsandaﬃnityconstantsofmolec-
ular interactions. We describe here an application that could
have a signiﬁcant impact on the study of antibody/liposome
interactions. Earlier studies demonstrated the feasibility
of biosensor simulation for acquiring binding data and
predicting targeting performance. The study of PEGylated
liposome formulations with variable PEG 2000 fractions
and diﬀerent PEG chain sizes (PEG 1000 and PEG 750)
by SPR prompted us to perform further pharmacokinetics
experiments to obtain the necessary information to improve
immunotargetinginvivo.Thismethodwillalsobeappliedto
other kinds of particulate nanovectors.
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koﬀ: Dissociation rate
kon: Association rate
KD: Dissociation constant
LUV: Large unilamelar vesicle
MAb: Monoclonal antibody
NHS: N-hydroxysuccinimide
PBS: Phosphate buﬀered saline
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